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Bevacizumab, an anti-vascular endothelial growth factor (VEGF-A) antibody, is used in metastatic colorectal carcinoma (CRC)
treatment, but responses are unpredictable. Vascular endothelial growth factor is alternatively spliced to form proangiogenic VEGF165
and antiangiogenic VEGF165b. Using isoform-specific enzyme-linked immunosorbent assay and quantitative polymerase chain reaction,
we found that over 90% of the VEGF in normal colonic tissue was VEGFxxxb, but there was a variable upregulation of VEGFxxx and
downregulation of VEGFxxxb in paired human CRC samples. Furthermore, cultured colonic adenoma cells expressed predominantly
VEGFxxxb, whereas colonic carcinoma cells expressed predominantly VEGFxxx. However, adenoma cells exposed to hypoxia
switched their expression from predominantly VEGFxxxb to predominantly VEGFxxx. VEGF165b overexpression in LS174t colon
cancer cells inhibited colon carcinoma growth in mouse xenograft models. Western blotting and surface plasmon resonance showed
that VEGF165b bound to bevacizumab with similar affinity as VEGF165. However, although bevacizumab effectively inhibited the rapid
growth of colon carcinomas expressing VEGF165, it did not affect the slower growth of tumours from colonic carcinoma cells
expressing VEGF165b. Both bevacizumab and anti-VEGF165b-specific antibodies were cytotoxic to colonic epithelial cells, but less so
to colonic carcinoma cells. These results show that the balance of antiangiogenic to proangiogenic isoforms switches to a variable
extent in CRC, regulates tumour growth rates and affects the sensitivity of tumours to bevacizumab by competitive binding. Together
with the identification of an autocrine cytoprotective role for VEGF165b in colonic epithelial cells, these results indicate that
bevacizumab treatment of human CRC may depend upon this balance of VEGF isoforms.
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Solid tumour growth is dependent on the induction of their own
blood supply by inducing a proangiogenic state in the tissue
environment, regulating this balance between proangiogenic
growth factors and antiangiogenic inhibitors (Folkman, 1985,
1995; Boehm et al, 1997). One growth factor that has been shown
to be an effective target for antiangiogenic therapy (AAT) is
vascular endothelial growth factor-A (VEGF-A). Inhibition of
VEGF by humanised monoclonal antibodies has been shown to be
effective in increasing the median survival in metastatic colorectal
cancer (CRC) when combined with chemotherapy (Hurwitz et al,
2004).
Vascular endothelial growth factor-A is generated by alternative
splicing from eight exons within the VEGF-A gene. All isoforms
contain exons 1–5 and the terminal exon, exon 8. Exons 6 and 7,
which encode heparin-binding domains, can be included or
excluded. This gives rise to a family of proteins termed according
to their amino-acid number, VEGF165, VEGF121, VEGF189 and so
on. Exon 8, however, contains two 30 splice sites in the nucleotide
sequences, which can be used by the cell to generate two families of
isoforms with identical length, but differing C-terminal amino-acid
sequences (Bates et al, 2002). VEGFxxx, the proangiogenic family of
isoforms, is generated by use of the most proximal sequence in
exon 8 (resulting from inclusion of exon 8a). The more recently
described VEGFxxxb isoforms are generated by the use of a distal
splice site, 66bp further along the gene from the proximal splice
site. This results in splicing out of exon 8a and the production of
mRNA sequences that encode the VEGFxxxb family (Bates et al,
2002). The two resultant families of proteins are of the same
length, but with different carboxyl termini. VEGF165b was the first
of these exon 8b-encoded isoforms identified and subsequent
studies demonstrated the existence of VEGF121b, VEGF183b,
VEGF145b (Perrin et al, 2005) and VEGF189b (Miller-Kasprzak
and Jagodzinski, 2008).
The functional consequences of this altered C terminus are that
VEGF165b homodimers compete with VEGF165 homodimers for
binding to their principal receptor, VEGFR-2, at a one-to-one ratio
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(Woolard et al, 2004; Cebe Suarez et al, 2006). VEGF165b blocks
VEGF165-driven angiogenesis in vivo in the rabbit, rat (Woolard
et al, 2004), mouse and chick (Cebe Suarez et al, 2006), and human
malignant melanomas consisting of cells overexpressing VEGF165b
and cells expressing VEGF165 grow slower in nude mice than those
consisting of cells expressing VEGF165 alone. Recombinant human
VEGF165b is also antiangiogenic in hypoxia-driven angiogenesis in
the eye (Konopatskaya et al, 2006).
Although VEGF has been shown to be critical in CRC by
inhibition studies, the expression of VEGF in CRC has not been
investigated using tools that distinguish between the proangio-
genic VEGFxxx isoforms and the antiangiogenic VEGFxxxb iso-
forms. The vast majority of studies have measured total VEGF
levels in plasma, tumours or serum using commercially available
antibodies that do not distinguish between pro- and antiangio-
genic isoforms, as commercial enzyme-linked immunosorbent
assays (ELISAs) detect VEGFxxxb isoforms. Furthermore, it is not
known whether the VEGFxxxb isoforms are able to slow or reduce
tumour growth if they are highly expressed. To determine whether
this antiangiogenic isoform family is expressed in CRC, and how
that expression may be regulated, this study compares the balance
of expression of the VEGFxxxb family of isoforms in human CRC
with paired normal colonic mucosa samples and show how the
expression of VEGFxxxb and VEGFxxx is altered during the
malignant transformation of colonic adenoma cells in vitro.
Furthermore, to determine whether this balance has the potential
to regulate tumour growth rates, we have measured VEGF165b
functional effects on colon carcinoma growth in animal models
where the tumour growth was VEGF-dependent. Furthermore, we
assess whether bevacizumab either specifically binds VEGFxxx
(proangiogenic) isoforms, or also has cross-reactivity with
antiangiogenic VEGF165b and whether it inhibits VEGF165b-
expressing tumours.
MATERIALS AND METHODS
Human tissue samples
Paired colon samples were from partial colon resection for
carcinoma. Samples were obtained by taking biopsies of the fresh
specimen from a nonnecrotic central portion of the tumour and
from a peripheral part of the macroscopically normal colonic
epithelium (n¼18 pairs). Samples were collected with Local Ethics
committee approval. The mean patient age was 71.5 (range 58–80)
years, with 62% male subjects and Duke’s staging as follows: 6.7%
A, 46.7% B and 46.7% C. Biopsies were immediately frozen in
liquid nitrogen and then stored at  801C until processed. Biopsies
were frozen in liquid nitrogen again immediately prior to manual
slicing with a sterile blade. The mass of each tissue was recorded,
and samples were homogenised and mRNA and protein extracted
as described below.
Expression analysis
For each of eight pairs of samples, mRNA was extracted from
approximately 200mg of tissue (Chomczynski and Sacchi, 1987)
and reverse transcribed as previously described (Bates et al, 2002).
The cDNA was amplified using primers complementary to VEGF
exon 7 and the 30-UTR downstream of exon 8b, as previously
described (Bates et al, 2002). The products were subjected to
standard agarose gel electrophoresis and ethidium bromide
staining. Protein was extracted from approximately 250mg tissue,
from 18 pairs of samples, resolved by 12% sodium dodecyl
sulphate-polyacrylamide gel electrophoresis, transferred and
immunoblotted as previously described (Woolard et al, 2004).
Briefly, membranes containing recombinant human VEGF165 and/or
VEGF165b protein (50ng of each) and protein samples extracted
from colon (100mg of each) were probed with mouse anti-
VEGFxxxb IgG (2mgml
 1 A56/1; R&D Systems, cat no. MAB3045)
(Woolard et al, 2004) or rabbit anti-VEGF IgG (1mgml
 1 A-20;
Santa Cruz Biotechnology, Santa Cruz, CA, USA) and detected with
horseradish peroxidase-conjugated stabilised goat anti-mouse or
anti-rabbit IgG (1/7000; Pierce Biotechnology, Rockford, IL, USA).
Visualisation of protein bands was achieved with SuperSignal West
Femto Maximum Sensitivity Substrate Kit (Pierce Biotechnology).
Quantitative RT-PCR
Quantitative PCR assays were carried out on cDNA generated as
above. An exon 7b forward primer and a 30-UTR primer (both pan-
VEGF quantitative polymerase chain reaction (Q-PCR) from
Primer Design, Southampton, UK) or an exon 7a forward primer
50-TTGCTCAGAGCGGAGAAAGC-30and a reverse primer specific
for exon 8a that did not detect VEGFxxxb isoforms 50-TCACCG
CCTCGGCTTGTCACAT-30 were used. Reactions were performed
using a SmartCyclerII (Cepheid, Sunnyvale, CA, USA) q-PCR
machine, with 25ml reaction volumes comprising 12.5ml Quanti-
tect SYBRgreen 2  master mix (Qiagen, Crawley, UK), 1ml cDNA
and 1ml primer mix cycled at 951C for 15min followed by 50 cycles
of 601C for 30s, 721C for 60s, 791C for 15s (reading) and 951C for
30s. A melt curve was then performed by ramping the temperature
from 60 to 951C at 0.21C per second, reading throughout. DNA
standards used were VEGF165b or VEGF165 cloned into pcDNA3, or
oligonucleotides containing the full sequence between the primers
(Primer Design).
Figures 1A and B show examples of the reverse transcription-
polymerase chain reaction (RT-PCR) curves for VEGF165b and
VEGF165 templates respectively using pan-VEGF primers.
Figure 1C shows the standard curve generated from cycle threshold
for the two templates, showing that there was no difference in the
standard curves (n¼3). Thus the efficiency of amplification of the
two templates is not different. Figure 1D shows the amplification
curves for the exon 8a primers using the VEGF165 sequence as a
template (VEGF165b template did not result in amplification until
18 cycles later than equivalent VEGF165 concentration). Total
VEGF and VEGFxxx copy numbers were calculated for each sample
using the calibration curve shown in Figure 1E. The difference
between the total VEGF and the VEGFxxx copy number was
assumed to be the VEGF165b copy number.
Immunohistochemistry
Immunohistochemistry was performed on formalin-fixed paraffin-
embedded normal colonic mucosa, obtained with local ethics
committee approval from archival material as previously described
(Woolard et al, 2004). Sections were stained with either mouse
monoclonal anti-VEGFxxxb IgG (8mgml
 1; R&D Systems, cat no.
MAB3045) or 5mgml
 1 mouse anti-VEGF IgG (Santa Cruz; SC-
7269) or a normal mouse IgG (Sigma Aldrich, Gillingham, UK;
I8765), as a negative control.
ELISAs
pan-VEGF mouse capture antibody (0.1mg) (Duoset VEGF ELISA
DY-293; R&D Systems, Minneapolis, MN, USA) diluted in 1 
phosphate-buffered saline (PBS) (pH 7.4) was adsorbed onto each
well of a 96-well sterile plate (Immulon 2HB Thermo Life Sciences,
Basingstoke, UK) or, for the VEGFxxxb ELISA, 0.08mg AF293-NA
Goat anti-VEGF polyclonal IgG (R&D Systems), overnight at room
temperature. The plates were washed three times between each
step with 1  PBS-Tween (0.05%). After blocking with bovine
serum albumin in PBS for 30min at 371C, recombinant human
VEGF165 standards or VEGF165b (R&D Systems) diluted in
blocking solution (ranging from 62.5pgml
 1 to 2ngml
 1)o r
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at 371C with shaking and three washes, 100ml of biotinylated goat
anti-human VEGF (50ngml
 1 in blocking solution; R&D Systems)
or a mouse monoclonal anti-VEGFxxxb-biotinylated IgG (clone
264610/1; R&D Systems) at 0.4mgml
 1 was added to each well, and
plates left for 30min at 371C with shaking. Streptavidin-HRP
(100ml) (R&D Systems) at 1:200 dilution in PBS was added,
plates left at room temperature for 20min and 100ml per well
O-phenylenediamine dihydrochloride solution (Substrate reagent
pack DY-999; R&D Systems) added, protected from light and
incubated for 20min at room temperature. The reaction was
stopped with 100ml per well 1moll
 1 H2SO4 (10276; BDH
Chemicals, Poole, UK), and absorbance read immediately in an
Opsys MR 96-well plate reader (Dynex Technologies, Chantilly,
VA, USA) at 492nm, with control reading at 460nm.
Characterisation of the ELISA
We used both this antibody (MAB3045) and a separate antibody
generated against the terminal nine amino acids of VEGF165b,
raised by R&D Systems and biotinylated (clone 264610/1), to
quantitate the relative levels of VEGF165b. Both VEGF165b
antibodies were as sensitive as the commercially available VEGF
ELISA (see Figure 2A). The biotinylated 264610/1 antibody
specifically detects VEGF165b, is accurate down to below
62.5pgml
 1 VEGF165b and does not detect VEGF165, even at
4ngml
 1 in an ELISA (Figure 2B). Both antibodies were used to
determine the amount of VEGFxxxb in human tissues from
pancreatic islets, placenta, lung, colon and prostate. The two
ELISAs did not differ in their results (e.g., colon tissue,
130±40pgmg
 1 MAB3045 ELISA 128±20pgmg
 1 clone
264610/1 ELISA, N¼18). The biotinylated 264610 ELISA was used
to quantitate the amount of VEGF in tissue samples, as it was more
sensitive, a simpler procedure, could use commercially available
capture antibodies and the protocol was most comparable to the
commercial VEGF DuoSet ELISA. To determine whether VEGF165
could interfere with this VEGF165b ELISA, serial dilutions of
rhVEGF165 were assayed. As seen in Figure 2B, there was no
significant change in OD values by the addition of rhVEGF165
as high as 4000pgml
 1, indicating that the VEGFxxxb
ELISA specifically detects VEGF165b, and is not affected by the
conventional VEGF isoform, VEGF165.
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Figure 1 Quantification of mRNA expression of pan-VEGF and VEGFxxx isoform mRNA by Q-PCR. (A and B) Primers that detected all isoforms were
used to detect increasing amounts of VEGF165b( A) or VEGF165 (B). (C) Standard curves for the two isoforms were the same indicating that a mixture of
both could be assessed equally. (D) Amplification of VEGFxxx cDNA specifically. Primers specific to exon 8a resulted in amplification that was more than six
orders of magnitude more sensitive for VEGF165 than VEGF165b (dotted line). (E) Standard curve using VEGF165 as a template.
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Figure 2 Quantification of VEGFxxxb protein expression by ELISA. (A)
Sensitivity of VEGF165b-specific antibody 264610/1 was determined using a
sandwich ELISA. Increasing concentrations of VEGF165b (for clone 264610/
1 and MAB3045) or VEGF165 (for R&D DuoSet, R&D Systems,
Minneapolis, MN, USA) were incubated with a goat anti-VEGF capture
antibody, then detected by either biotinylated 264610/1 mouse anti-VEGF
(R&D Duoset) or MAB3045 and a biotinylated secondary antibody. (B)
Specificity of the VEGF165b ELISA using biotinylated 264610/1 was
determined by incubating increasing concentrations of human recombinant
VEGF165b, or VEGF165 with a pan-VEGF capture antibody adhered to the
plate, then detecting with biotinylated 264610/1. (C) The commercially
available ELISA is less sensitive for VEGF165b than for VEGF165. Increasing
concentrations of protein (determined by Bradford Assay) were incubated
with a mouse monoclonal capture antibody and detected with a
biotinylated mouse-pan-VEGF capture antibody. VEGF165b was under-
estimated by 42%. The lower affinity of the capture antibody for VEGF165b
was confirmed by Biacore. sFlt-1 did not interfere with this ELISA.
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detected VEGF165b, we carried out a VEGF ELISA using increasing
concentrations of VEGF165b. Figure 2C shows that increasing
concentrations of VEGF165b were detected by the R&D Duoset kit –
the most widely used ELISA. Interestingly, this ELISA detects
VEGF165b at a lower affinity than VEGF165. The ratio of the slopes
is 0.42±0.004 or 42±0.4%. To confirm this, we used VEGF165b
generated from two different sources – R&D Systems and an in-
house production (both proteins were quantitated by Bradford
Assay). The R&D Duoset Kit (DY293B) is a second generation
ELISA introduced in 2004. We are unaware of published
information on sFlt-1 interference in the current DuoSet kit.
Figure 2C shows that increasing concentrations of sFlt-1 did not
affect the pan-VEGF ELISA at least up to 2000pgml
 1 VEGF.
With the previous ELISA, VEGF165b levels were detected at 100%
of VEGF165, indicating that the previous ELISA kit had the same
affinity for both isoforms. To ensure that this was due to a
difference in affinity of the antibodies for the two isoforms, we
carried out surface plasmon resonance analysis of binding
coefficients.
Surface plasmon resonance
To compare the binding affinities of VEGF165 and VEGF165b to the
pan-VEGF antibody used in the R&D Duoset detection kit, we
amine-coupled the latter to a CM5 sensor chip (Biacore AB,
Uppsala, Sweden) to an immobilisation level of 630 response units
(RU). To compare the binding affinities of VEGF165 and VEGF165b
to bevacizumab, the latter was amine-coupled to a CM5 sensor
chip (Biacore AB) to an immobilisation level of 580 RU. The
coupling was performed using EDC/NHS and 1moll
 1 ethanola-
mine (Biacore) as per the manufacturer’s instructions, with the
bevacizumab dissolved in 10mmoll
 1 sodium acetate (pH 4.5). A
blank reference cell was formed by the same activation and
deactivation process involved in amine coupling without adding
antibody. Samples containing VEGF165 or VEGF165b diluted in
HBS-EP sample buffer (Hepes-buffered saline with EDTA and P20
surfactant, Biacore AB) were then run at twofold serial dilutions
from 180nmoll
 1 down, in random order in duplicate. Injection
was performed at 30mlmin
 1 for 3min, followed by 6min of buffer
only, for monitoring of dissociation. Regeneration between each
interaction was performed by injection of 4moll
 1 MgCl2 at
20mlmin
 1 for 40s, followed by a 2-min period of stabilisation
before the next injection. Figure 3A shows the binding curves of
VEGF165 to the RnD detection antibody and Figure 3B shows
binding of VEGF165b to the same antibody. The RnD detection
antibody had a higher association coefficient for VEGF165 than
VEGF165b and a lower dissociation coefficient for VEGF165 than
VEGF165b (Figure 3C), resulting in an affinity of 602pM for
VEGF165,b u t3 . 9 8n M for VEGF165b, an B6.6-fold difference in affinity,
indicating that the underestimation of the commercial ELISA for
VEGF165b was due to a difference in affinity for the antigen.
The actual VEGF concentrations (VEGFtotal) in human tissue are
the sum of VEGFxxx and VEGFxxxb.
VEGFtotal¼ VEGFxxxþVEGFxxxb
The commercially available pan-VEGF ELISA has a lower affinity
for VEGF165b than for VEGF165 by 42%. Therefore the measured
VEGF levels (VEGFmeasured) in the commercially available ELISA
are the sum of VEGF165 and 42% of VEGF165b.
VEGFmeasured¼ VEGFxxxþð0:42 VEGFxxxbÞ
Therefore;
VEGFtotal¼ VEGFmeasuredþ0:58 VEGFxxxb
We used the above correction to estimate tissue concentration of
VEGFxxxb and its relative proportion of total VEGF.
Adenoma-carcinoma cell VEGF expression
Colonic adenoma cells (AAC1) and their in vitro-derived
carcinoma cells (10C) were kindly donated by Professor C
Paraskeva (Williams et al, 1990). The adenoma cells are a
non-tumour-forming clonogenic variant of the PC/AA cell line
derived from a polyp from a patient with familial adenoma
polyposis (Paraskeva et al, 1988). The cells were cultured to 100%
confluence in Dulbecco’s modified Eagle’s medium supplemented
with 20% fetal bovine serum, 1% penicillin/streptomycin and
0.2% Actrapid insulin (Novo Nordisk, Crawley, UK). Protein
was extracted from confluent cells in fresh media as above cells
were placed in a hypoxic chamber (Billups-Rothenburg, Del Mar,
CA, USA) for 5min at 20lmin
 1 with 5% CO2/nitrogen gas
mixture (BOC) and incubated at 371C. The gas was changed twice
per day.
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Figure 3 The commercially available VEGF antibody has a lower affinity
for VEGF165b than VEGF165. The mouse detection antibody from the R&D
ELISA Duoset was immobilised on a sensor chip, and VEGF isoforms
allowed to flow over the detecting chip. (A) VEGF165 resulted in an
increase in signal upon loading (arrow 1), which reduced on replacement
with wash solution (arrow 2). (B) With the same set up, VEGF165b was
also detected, but the response rate was slower, and the release was faster.
(C) Association and disassociation coefficients calculated using Langmuir
1:1 binding analysis. (D) Affinity coefficient calculated from the dissociation
and association constants measured. The antibody has approximately an
6.6-fold weaker affinity for VEGF165b than VEGF165.
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LS174t human colon carcinoma cell lines were used (ECACC,
Salisbury, UK) (Yuan et al, 1996; Lee et al, 2000). Cells were
transfected with 1mg of purified plasmid pcDNA3 either as empty
vector, with VEGF165, VEGF165b, or both VEGF165 and VEGF165b
vectors, using Lipofectamine Plus (Invitrogen, Carlsbad, CA, USA)
as per the manufacturer’s instructions. Cells were selected using
geneticin (500mgml
 1). Conditioned media were analysed by
ELISAs for VEGF and VEGFxxxb production per cell per 24h, to
confirm expression levels of VEGF isoforms. A total of 2 10
6 cells
were injected subcutaneously into the lumbar region of nude mice
(six per group unless otherwise stated). Mice were then monitored
every 2–3 days and tumour length and width measured. When the
first tumour reached 16mm in maximum diameter, all mice were
killed. Tumour volumes were calculated according to the formula
(length width (lengthþwidth)/2). Injections, measurements
and analysis were all carried out with the investigators blinded
to group.
Cytotoxicity
Measurement of the cell-cytotoxicity effects of blocking VEGF
isoforms was performed using a lactate dehydrogenase (LDH)
assay following exposure of the cells to various antibodies and
RTKIs as described in the results. Cells were grown to 90–100%
confluence in 96-well plates prior to treatment in serum-free
medium, against which treatment was compared. A Cytotox 96
Non-Radioactive Cytotoxicity Assay (Promega Corp, Madison, WI,
USA, no. G1780) was used according to the manufacturer’s
instructions.
Statistics
Means and standard errors are given unless stated otherwise.
Tumour volumes, cell cycle parameters and apoptosis were
compared by one-way analysis of variance (ANOVA) followed by
a Bonferroni post-hoc test. Tumour growth curves were fitted by
nonlinear regression using an exponential curve fit in Prism.
Doubling times were calculated from 0.69k
 1, and are given as
mean (95% confidence intervals (CI)), and curve-fitting para-
meters compared using an F-test. Analysis of ELISA results was
performed using Wilcoxon’s signed matched ranks at 95%
significance level (two-tailed).
RESULTS
Normal colonic epithelial cells and colonic carcinomas
expressed VEGF165b mRNA
To determine whether VEGF165b and VEGF165 mRNA were
expressed in normal and cancerous colon, RT-PCR using primers
that distinguish between the two families of isoforms was carried
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Figure 4 VEGF165b mRNA is expressed in human colon tissue and colon cancer. (A) VEGFxxxb mRNA is expressed in normal and cancerous colon. PCR
of cDNA reverse transcribed from RNA extracted from paired human colon samples shows two bands, the proximal splice isoforms (VEGFxxx, B200bp)
and the distal splice isoforms (VEGFxxxb, B135bp). (B–D) Q-PCR for pan-VEGF (VEGF165b and VEGF165) and VEGF165 isoforms. (B) Primers that
detected all 165 amino acid-coding isoforms were used to detect increasing amounts of total VEGF (VEGF165b and VEGF165). (C) Exon 8a-specific primers
were used to measure the amount of VEGF165, which was significantly increased in colon cancers, Po0.01. (D) VEGF165b levels calculated from the VEGF165
and total VEGF levels.
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sout on eight pairs of samples. Reverse transcription-polymerase
chain reaction gave two bands, one at B135bp, consistent with
VEGF165b or VEGF189b, and one at B200bp, consistent with
VEGF165 and VEGF189. This size difference was due to the splicing
out of exon 8a in the VEGFxxxb family, resulting in the shorter
mRNA (although exon 8b is present in the mRNA of the VEGFxxx
family, a stop codon in exon 8a prevents its translation). VEGFxxx
and VEGFxxxb mRNA expression was detected in both normal and
tumour tissue (Figure 4A).
VEGF mRNA is differentially spliced in colon cancer
Quantitative PCR on mRNA extracted from seven pairs of
colorectal normal and tumour tissue demonstrated that the
VEGFxxx mRNA copy number was only 9.1±2.8% of the total
VEGF level in normal tissues, indicating that VEGFxxxb species
form more than 90% of the mRNA. There was an increase in copy
number of all VEGF isoforms from 5±2.2 to 11±3.5  10
3 copies
per mg of tissue (Figure 4B). This upregulation was specific for the
VEGF165 isoform (0.18±0.32 to 6.0±2.6 10
3 copies per mg,
Figure 4C, Po0.01, ANOVA), and not for the VEGF165b isoform
(4.8±2.2 to 5.6±2.0 10
3 copies per mg, Figure 4D), such that in
cancers, 45±13% of the VEGF mRNA was VEGF165.
VEGF165b and VEGF121b protein are expressed in normal
and cancerous colon
To determine whether protein expression of VEGFxxxb isoforms
was present in normal and tumour tissues, western blotting and
ELISA were carried out using antibodies specific to VEGF165b and
antibodies that do not distinguish between isoforms. The
previously characterised anti-VEGF165b antibody (R&D Systems,
cat no. MAB3045) demonstrates highly specific binding to
recombinant human VEGF165b but not to recombinant human
VEGF165 (Pritchard-Jones et al, 2007). Figure 5A shows that both
VEGF121b and VEGF165b were expressed in both normal colonic
VEGF (total)
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Figure 5 VEGFxxxb is the predominant family of VEGF proteins in normal colon but not in colon cancer. (A) Western blots of VEGFxxxb expression in
normal and cancerous colon. Two strong bands are seen in each tissue, consistent with VEGF165b and VEGF121b. Longer isoforms are very faintly visible,
indicating VEGF183b and VEGF189b. C¼control, T¼tumour, rhVEGF165¼recombinant human VEGF165, VEGF165b¼recombinant human VEGF165b
(unglycosylated). (B–D) Immunohistochemical staining of normal colonic mucosa. (B) Staining with an antibody that recognises only the VEGFxxxb isoforms.
(C) Staining with an antibody that recognises all VEGF isoforms. (D) Control IgG stain. Vascular endothelial growth factor and VEGFxxxb were localised to
the brush border epithelial cells (BBEpC), goblet cells (GC) of the intestinal glands (Gl) and to some, but not all, plasma cells of the lamina propria (LP). Scale
bar¼50mm. (E–G) Measurement of total VEGF (E) and VEGFxxxb( F) expression in normal and cancerous colon. VEGFxxx but not VEGFxxxb, was
upregulated in colorectal carcinoma mean values shown by open circles. (G) VEGFxxx is present in excess over VEGFxxxb in CRC, but not in normal tissue.
Excess VEGFxxx (values greater than 1) results in a proangiogenic environment, whereas excess VEGFxxxb (values less than 1) results in an antiangiogenic
environment.
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determine which cells in colonic epithelium expressed the
VEGFxxxb isoforms, we used immunohistochemistry to stain the
normal colon samples. Figure 5B shows that VEGFxxxb was highly
expressed in colonic epithelial cells of the brush border (especially
cells at the apex of the villi), cells within the lamina propria with
plasma cell morphology and goblet cells. Staining of sections with
the VEGF antibody that recognises all VEGF isoforms (including
VEGFxxxb isoforms, Figure 5C) showed that VEGF was expressed
in all the places where VEGF165b staining was apparent.
Nonspecific isotype control IgG did not stain (Figure 5D).
Increased VEGF protein levels in cancer are restricted to
the angiogenic isoforms
To determine whether the previously reported increase in VEGF
expression (Ellis et al, 2000; Reinmuth et al, 2003) in CRC was due
to changes in VEGFxxxb or VEGFxxx, the levels of VEGF and
VEGFxxxb were determined by ELISA and isoform-specific ELISA
respectively. Total VEGF was significantly upregulated in CRC
(288±48pg VEGF per mg total protein) compared to normal
colon (122±23pgmg
 1, n¼18; Po0.01, Wilcoxon Figure 5E).
VEGFxxxb concentrations, however, were no different in tumour
extracts (160±50pgmg
 1) than in controls (130±23pgmg
 1;
P¼0.96, Figure 5F). Since the total VEGF is the sum of the pro-
and antiangiogenic isoforms, the level of VEGFxxx expression was
calculated in these samples. The mean VEGFxxx concentration in
normal mucosa was not significantly different from zero. In CRC
tissue, however, the mean VEGFxxx level was 128±53pg per mg
total protein, indicating that the difference in total VEGF
expression was due to an upregulation in VEGFxxx production
alone. Thus, there was a shift from predominantly VEGFxxxb
protein in controls to VEGFxxx in CRC (mean±s.e.m. ratio
VEGFxxxb/total VEGF: 112±12% in controls, 59±12% in tumours;
Po0.001 paired t-test). Figure 5G shows that the ratio of VEGFxxx
to VEGFxxxb in the tumours was highly variable with some patients
having no excess of VEGFxxx, and others up to 57-fold excess of
VEGFxxx. There was no relationship between Dukes’ staging and
VEGFxxxb concentration or proportion (P¼0.75; one-way ANO-
VA, data not shown).
The switch in expression is part of the malignant
transformation program
As VEGF expression is predominantly proangiogenic in CRC and
predominantly antiangiogenic in normal colonic epithelium, cell
lines at different stages of the malignant transformation may
reflect this. Cells along the adenoma-carcinoma sequence, grown
in 100% confluent monolayers, were assayed for VEGF expression
as shown in Figure 6. Although the total VEGF expression
increased along the adenoma-carcinoma sequence, the degree to
which it did so was very variable (Figure 6A) and only the LS174t
cells demonstrated a significant such increase. In addition, the
VEGFxxxb expression was reduced in the carcinoma cells compared
to the adenoma cells, but this only reached significance in the
HT29 cell line (Figure 6B). Overall, the effect of a shift from anti- to
proangiogenic VEGF expression predominance in CRC cell lines
was due to a combination of reduced VEGFxxxb expression and
increased VEGFxxx expression, resulting in a shift from 82±10%
VEGFxxxb in adenoma cells to between 5.7±0.3 and 53±5.8% in
the carcinoma cell lines (Po0.0001, one-way ANOVA, Figure 6C).
There was thus a predominance of VEGFxxxb in this adenoma cell
line, and a variable switch towards predominance of VEGFxxx in
the colonic carcinoma cell lines.
To test whether hypoxic upregulation of VEGF expression
induced a switch in the relative expression of pro- and
antiangiogenic VEGF required the use of cell lines that produced
predominantly VEGFxxxb in normoxia, such as AAC1 and 10C. The
exposure of the AAC1 cells to hypoxia resulted in a switch from
predominantly antiangiogenic VEGFxxxb (82±10% VEGFxxxb) to
predominantly proangiogenic VEGFxxx (65±1% VEGFxxx; Po0.01,
Figure 6D). This change in the AAC1 cells was due to an
upregulation in the proangiogenic isoforms of VEGF, since total
VEGF increased (Po0.01, Table 1) but VEGFxxxb isoforms did not
significantly alter. Neither the total VEGF nor the VEGFxxxb
expression in 10C cells was significantly altered by hypoxia.
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Figure 6 Vascular endothelial growth factor balance shifts from anti- to
proangiogenic along the adenoma-carcinoma sequence in vitro. HT29,
LS174t and 10C well-differentiated adenocarcinoma cell lines and the 10C
parent, AAC1 adenoma cell line, were grown to 100% confluence and
VEGF expression measured by ELISAs. (A) Total VEGF expression
increased from adenoma to carcinoma. (B) In contrast, VEGFxxxb
expression decreased along this axis. (C) The ratio of VEGFxxxb to total
VEGF therefore decreased significantly. (D) Hypoxia reduced VEGFxxxb
expression in AAC1 adenoma but not in the 10C carcinoma cell lines.
One-way ANOVA with Newman–Keuls post-hoc tests, confirmed overall
((A): Po0.0001; (B): Po0.0004; (C): Po0.05, (D): Po0.001) and
individual differences indicated by *Po0.05, **Po0.01, ***Po0.001.
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sEffect of VEGF165b expression on colon cancer growth
rates
Prior to injection of the tumour cells into the mice, expression of
VEGF isoforms was measured both by western blotting and by
ELISA. Vascular endothelial growth factor concentrations of the
LS174t human colonic carcinoma cell line transfected to overexpress
VEGF165, VEGF165b, VEGF165 and VEGF165b( V E G F 165/165b), or with
the empty expression vector (pcDNA3) are given in Table 1.
Proliferation of LS174t cells after transfection with VEGF165,
VEGF165b, both or control vector was measured by flow cytometry.
Histogram analysis of propidium iodide-labelled cells showed that
there was no significant difference between the cell cycle stage of
the groups (control 79±2.3%, VEGF165 80±3%, VEGF165b
83±5% and VEGF165/165b7 7 ±0.7% in G0/G1; P40.1). Apoptosis
and necrosis were also measured by dual PI/Annexin V staining.
There were no significant differences between the four groups
(data not shown).
VEGF165b slows LS174t tumour growth in vivo
To determine whether VEGF165b expression by the tumour cells
inhibited tumour growth in vivo, LS174t human colon carcinoma
cells stably transfected to express VEGF165, VEGF165b, both
isoforms (VEGF165þVEGF165b), or a control vector were injected
into nude mice. Figure 7A shows that control-transfected cells
formed large vascular solid tumours within 15 days. Tumours
formed from cells overexpressing VEGF165b were smaller and less
vascularised (Figure 7B) and had a softer texture. Comparison of
tumour volumes made by caliper measurements in live animals
showed that VEGF165b-expressing cells formed significantly
smaller tumours than control cells (Po0.01, Figure 7C). Over-
expression of VEGF165 in LS174t cells resulted in large, vascular
tumours (Figure 7D). However, injection of cells expressing both
VEGF165 and VEGF165b resulted in smaller, paler tumours than
VEGF165 alone (Po0.001, Figures 7E and F). VEGF165b tumours
(0.33±0.22cm
3) were significantly smaller than the VEGF165-
expressing tumours (1.61±0.57cm
3; Po0.001) at 15 days.
Exponential curve fitting to the tumour growth curves was used
to calculate the doubling time of the tumour groups. The mean
(95% CI) doubling times for pcDNA3, VEGF165 overexpression and
VEGF165/165b overexpression were 2.1 (1.9–2.4), 1.9 (1.9–2.1) and
2.4 (2.2–2.6) days respectively. In comparison, the doubling time
for VEGF165b overexpression was 3.0 (2.5–3.6) days, which was
statistically significantly different (Po0.001) from the other
groups. After excision, tumour sections were stained with
haematoxylin and eosin, and areas of necrosis quantified
(Figure 7G). VEGF165b-expressing tumours had significantly
greater areas of necrosis compared with other groups
(Figure 7H; Po0.05 ANOVA).
Bevacizumab can bind VEGF165b
To determine whether bevacizumab bound VEGF165b, a western
blot of recombinant human VEGF165 and VEGF165b was carried
out by immunodetection with bevacizumab and secondary
antibodies to human IgG (Figure 8A). Bevacizumab appeared to
detect efficiently recombinant human VEGF165b. To determine the
efficiency of binding, and its affinity for VEGF165b, we carried out
Biacore analysis of bevacizumab covalently bound to a surface
plasmon resonance sensor. Figure 8B shows the association and
disassociation kinetics of VEGF165, and Figure 8C those for
VEGF165b across this chip (Figure 8D). The ratio of these two gives
the overall affinity (KD). The KD was similar for VEGF165 (2.5nM)
and VEGF165b (6.8nM).
VEGF165b inhibits the effect of bevacizumab
To determine whether the effect of bevacizumab on tumour growth
was dependent on VEGF165b expression, nude mice were injected
with either VEGF165b-transfected LS174t colon cancer cells
expressing 95% VEGF165b( n¼14), or control LS174t cells
expressing 94% VEGF165 (n¼12). Twenty-four hours after tumour
cell injection, bi-weekly treatment with 50mg bevacizumab or
saline was started, and tumour sizes measured every 3–4 days.
Figure 9A shows that bevacizumab significantly inhibited the
growth of VEGF165-expressing colon cancer cells (Po0.05) within
15 days. Figure 9B shows that even after 35 days of treatment,
bevacizumab had no effect on tumour growth in cells expressing
predominantly VEGF165b. To determine whether the effect of
bevacizumab on previously established tumours was modified by
VEGF165b, cells were injected as before, and tumours allowed to
grow to 4mm in diameter before treatment with bevacizumab as
above. Figure 9C shows that bevacizumab inhibited the growth of
established tumours compared with saline treatment (Po0.05),
whereas Figure 9D shows that it did not affect the growth of
VEGF165b-expressing tumours. Figure 9E shows that VEGF165b-
expressing tumours grew faster than those not expressing
VEGF165b when treated with bevacizumab (Po0.05).
VEGF inhibition is toxic to colonic epithelial cells
VEGF165b is strongly expressed in normal colonic tissue and by
AAC1 colonic adenoma cells and has been shown to be
cytoprotective in renal epithelial cells. Therefore, the sequestration
of VEGF165b by addition of either a specific anti-VEGFxxxb
antibody or a more general anti-VEGF antibody could be
cytotoxic. To explore this, AAC1 adenoma cells (normally express
B85% of their VEGF as VEGF165b) were treated with either an
anti-VEGF165b-specific antibody (R&D Systems, cat no. MAB3045)
or bevacizumab at increasing doses for 48h. Cytotoxicity was
measured by assaying supernatant for lactate dehydrogenase.
Figure 10A shows that VEGF165b inhibition was toxic to AAC1 cells
in a dose-dependent manner, increasing the cytotoxicity by
14.4±1.1-fold (Po0.001). Bevacizumab also significantly in-
creased cytotoxicity 4.9±0.5-fold (Po0.001). A nonspecific IgG
(1mgml
 1) resulted in a modest 2.2±0.25-fold increase in
cytotoxicity over baseline in AAC1 cells (Po0.01). Much smaller
increases in cytotoxicity were seen when LS174t colonic carcinoma
cells were treated with the anti-VEGF165b antibody (4.0±0.35-fold)
or bevacizumab (3.2±0.6-fold) (Figure 10B, no increase seen with
nonspecific IgG). To confirm that the cytotoxicity effects of anti-
VEGF antibodies were due to inhibition of VEGFxxxb, the effects
of supplementing the media with rhVEGF165b were measured
(Figure 10C). Addition of 40ngml
 1 rhVEGF165b protein
abolished cytotoxicity induced by the VEGF165b antibody
(Po0.01, one-way ANOVA).
To evaluate whether the VEGF165b required for AAC1 cell
survival was acting through VEGFR1 or VEGFR2, cells were treated
with receptor tyrosine kinase inhibitors to selectively inactivate
each of these receptors. Selective inhibition (Glass et al, 2006) of
either VEGFR1 (10nM SU5416) or VEGFR2 (200nM ZM323881)
was not toxic to the AAC1 cells (Figure 10D), but combined
inhibition of both receptors induced a significant increase in
Table 1 VEGF concentrations in transfected cells
PcDNA3 VEGF165b VEGF165
VEGF165b
and VEGF165
LS174t cells fg VEGF per cell per day
Total VEGF 4.1±0.4 9.9±1.2* 7.0±0.2* 35.4±0.2*
VEGF165b Undetectable 7.6±0.03* Undetectable 13.3±0.06*
VEGF165 4.1±0.4 2.3±0.03 7.0±0.2* 22.1±0.2*
Abbreviation: VEGF, vascular endothelial growth factor. *Po0.05 compared with
pcDNA3.
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scytotoxicity (1.8±0.29-fold; Po0.05, one-way ANOVA), an effect
that could be rescued by the addition of 100ngml
 1 of either
rhVEGF165 or rhVEGF165b protein.
DISCUSSION
Vascular endothelial growth factor has been identified in
thousands of studies as being altered in tumours, and able
to affect tumour growth. VEGF165 was originally identified
from tumours and tumour cells, showed angiogenic and
propermeability activity and was generated from the sequence
now described as exon 8a. In 2002, we described VEGF165b,
encoded by an alternative sequence in exon 8 (exon 8b), resulting
in a protein of identical length but different amino-acid sequence
to that encoded by exon 8a. This different C terminus is also found
in other VEGF isoforms, resulting in a family of VEGFxxxb
splice variants (Perrin et al, 2005) that is expressed in many
normal tissues and mirrors the conventional, angiogenic VEGFxxx
isoforms.
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Figure 7 VEGF165b inhibits colon cancer growth in vivo.( A) A total of 2 10
6 LS174t cells transfected with expression vector pcDNA3 injected
subcutaneously into nude mice resulted in tumours after 15 days that were large and bloody (excised tumour inset). (B) LS174t cells overexpressing
VEGF165b were smaller and paler. (C) Caliper measurements of tumours revealed that VEGF165b-expressing tumours grew significantly more slowly than
control tumours. (D) VEGF165-overexpressing LS174t cells injected subcutaneously into nude mice resulted in tumours that were large and very bloody. (E)
LS174t cells with a balance of VEGF isoforms resulted in smaller, paler tumours than those transfected with VEGF165 alone. (F) Tumours formed from cells
expressing both isoforms grew more slowly than those expressing VEGF165 demonstrating that VEGF165b inhibits VEGF165-mediated tumour growth. (G)
H&E staining of tumour sections was analysed for necrosis. (H) Tumours formed from LS174t cells overexpressing control or VEGF165 expression vectors
had significantly less necrosis than those expressing VEGF165b( * Po0.05, ***Po0.001).
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Homodimeric VEGF165b is a competitive antagonist of VEGFR2,
binding to it with affinity equal to that of VEGF165 (Woolard et al,
2004). Moreover, VEGF165b is not angiogenic, and can act as an
antiangiogenic agent in VEGF-mediated angiogenesis, such as in
the eye and in the mesentery (Woolard et al, 2004). We show here
that these antiangiogenic isoforms of VEGF are expressed as
mRNA and protein in both normal colonic epithelial cells and
colonic carcinomas. Not only is their expression dominant in
normal colonic epithelium, but also remains relatively constant in
the carcinomas. Many previous studies have identified VEGF
upregulation in colon carcinomas either without distinguishing
between the two families of isoforms or by methods that only
detect the proangiogenic isoforms. Previously described total
VEGF levels seen in normal and CRC samples are similar to those
described here (40 and 220pgmg
 1, respectively (Konno et al,
1998)). However, this is a significant underestimate of total VEGF,
as the commercially available ELISAs for VEGF have an affinity
for VEGF165b of only 42% compared with VEGF165. Thus, a more
accurate estimation of VEGF concentrations in tissues requires a
correction for this affinity. Here we show that the measured
amount of VEGFxxx, but not VEGFxxxb, is increased in CRC,
supporting the idea that there is a proangiogenic switch involving
upregulation of both VEGF overall and, crucially, of only the
proangiogenic splice variants.
However, our results show that the VEGF165b levels in some
tissues (approximately half of the normal samples) exceed those
of the total VEGF levels, measured by the pan-VEGF ELISA,
even after adjustment for the poor affinity of the pan-ELISA for
VEGF165b. There are a number of possible reasons for this
difference, although none has been clearly proven, mainly relating
to the lack of accuracy of the commercial pan-VEGF ELISA when
the VEGFxxxb isoforms are considered. These include (a)
endogenous heterodimerisation, (b) other isoforms and (c)
interference by other as yet unknown proteins and fats.
Endogenous heterodimerisation may yield intermediate forms
such as VEGF165b:VEGF165 or VEGF121b:VEGF165b. The affinity of
the pan-ELISAs for heterodimers has not yet been shown, but may
be intermediate between the two homodimers. If half the VEGF165
is dimerised with VEGF165b, then the true total VEGF value may be
still higher. Other isoforms of VEGFxxxb exist (Perrin et al, 2005),
but the affinity of the ELISAs for these (particularly the
commercially available pan-VEGF ELISA) has not been measured.
If the affinity of the commercial pan-VEGF ELISA for VEGF121bo r
VEGF121 was less than that for VEGF165b or VEGF165, then this
would also result in an underestimate of the total VEGF levels.
Finally, the soluble splice variant of VEGFR1 (sFlt-1) has been
shown to inhibit detection of VEGF in previous commercially
available pan-VEGF ELISAs (Maynard et al, 2003). We showed that
sFlt-1 does not interfere with the current R&D pan-VEGF ELISA,
ruling this out as an explanation for the discrepancy, but other
proteins, such as soluble VEGFR2, may affect binding. We show
here that VEGFxxxb is localised to the same regions of the colonic
mucosa as that previously thought to be for proangiogenic VEGF,
the lamina propria (Griga et al, 2002), goblet cells and glandular
cells of the mucosa (Griga et al, 1999) and our findings for the
pan-VEGF stain are consistent with this. The detection of the same
cells by the antibody raised specifically against VEGF165b, as by an
antibody to all VEGF isoforms, concurs with our ELISA findings
that in normal colonic mucosa it is the VEGFxxxb isoforms that
predominate. This has significant implications for interpretation of
all previous studies investigating VEGF expression in the colon,
not only for tumour studies (Hurwitz et al, 2004), but also for
collagenous (Griga et al, 2004) and ischaemic colitides (Okuda
et al, 2005).
Antiangiogenic VEGF tumour inhibition
The results here show that VEGF overexpression can alter the rate
of human xenografted tumour growth in vivo and moreover that
VEGF165b can antagonise the effects of VEGF165, thus confirming
the role of the C terminus of VEGF in determining its function and
the importance of the ratio of VEGFxxxb to VEGFxxx in the
progression of tumour growth. The ability of AAT to inhibit
xenografted tumour growth has been demonstrated previously
(Kendall and Thomas, 1993; Kim et al, 1993; Kanai et al, 1998;
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Figure 8 Bevacizumab binds to VEGF165b. (A) Western blot using
bevacizumab as the primary detection antibody. Human recombinant
VEGF165b or VEGF165 was run on a denaturing gel at increasing
concentrations. Both isoforms were detected by bevacizumab. Biacore
analysis of (B) VEGF165 and (C) VEGF165 b binding to bevacizumab. Curves
show dose-dependent increase in response units for both VEGF165b and
VEGF165, and dissociation after washout that results in similar binding
affinities. (D) Mean dissociation and association coefficients for VEGF165b
and VEGF165.
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sWildiers et al, 2003). The effectiveness of AAT has translated into
the clinic with bevacizumab in the treatment of renal (Yang et al,
2003), breast (Ramaswamy et al, 2006) and CRCs (Hurwitz et al,
2004). Furthermore, the ability of VEGF165b to inhibit VEGF165-
mediated angiogenesis in a rat mesenteric and rabbit corneal assay
(Woolard et al, 2004) and mouse retinal angiogenesis assay
(Konopatskaya et al, 2006) suggests that it may serve as a novel
AAT agent. Consistent with this, we show here that the over-
expression of VEGF165b in human CRC can inhibit tumour growth
in vivo, further supporting the potential role of relative VEGFxxxb
downregulation as part of the angiogenic switch in tumour
progression. Furthermore, neither VEGF165 nor VEGF165b over-
expression alters the in vitro proliferation or apoptosis rates of
cells, suggesting that the mechanism of action of VEGF in altering
tumour growth rate is not through an autocrine pathway, but likely
to be via its known antiangiogenic effects. Furthermore, the
antagonistic effects of VEGF165b overexpression on tumour growth
when co-overexpressed with the potent proangiogenic VEGF165
and the increased tumour necrosis observed when VEGFxxxb was
overexpressed further suggests that VEGF165b inhibits tumour
growth through antiangiogenesis.
Bevacizumab binds VEGF165b
Bevacizumab binds to all the conventional isoforms of VEGF (Kim
et al, 1992) via an epitope on the common region of the protein
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Figure 9 Bevacizumab does not inhibit growth of VEGF165b-expressing tumours. LS174t cells overexpressing VEGF165b or controls were implanted into
nude mice, and treated with twice weekly intraperitoneal injection of either saline or 50mg of bevacizumab. (A) Bevacizumab inhibited growth of LS174t
cells compared with saline-injected controls (Po0.01). (B) In contrast, bevacizumab had no effect on the growth of VEGF165b-expressing tumour cells
(P40.5). (C) LS174t cells overexpressing VEGF165b or control LS174t cells were implanted into nude mice, and allowed to form tumours of B4mm
diameter prior to treatment by twice weekly intraperitoneal injection of either 50mg of bevacizumab or saline. Bevacizumab inhibited growth of established
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sfamily, adjacent to the receptor-binding site (Muller et al, 1997). In
CRC, the response to bevacizumab is limited to a small subset of
patients, approximately 11–12%, but to date this subset has not
been shown to be predictable (Jubb et al, 2006). The results here
show that the affinity of bevacizumab was similar for VEGF165 and
VEGF165b and concur well with the results by Presta et al (1997).
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explained by VEGFxxxb expression. The relative expression levels
of the VEGFxxx isoforms in human colon carcinoma vary from only
27% of the VEGFxxxb isoforms to 60-fold excess, whereas in
normal colon, we did not detect excess of VEGFxxx over VEGFxxxb.
This can explain why in some patients bevacizumab could be a
highly effective antiangiogenic agent – those in which the vast
majority of the VEGF in their carcinomas is VEGFxxx (the
proangiogenic family), whereas in most, those with significant
VEGFxxxb expression, bevacizumab may be less effective. To date,
no biomarkers have been identified that can predict response to
bevacizumab (Ince et al, 2005; Jubb et al, 2006). The differential
response in the LS174t tumours to bevacizumab therapy in mice
depending upon VEGF165b-to-VEGF165 ratio shown here is
suggestive of its role as a potential biomarker in CRC and possibly
other cancers that are responsive to bevacizumab. It remains to be
seen whether patients with high levels of VEGF165b respond poorly
to bevacizumab, but this needs to be tested.
Vascular endothelial growth factor has been shown to be a
survival factor for several carcinoma types, including colon.
Transfection of RKO colon cancer cells with short interfering
RNA against the coding region of VEGF reduced cell proliferation
by 67% (Mulkeen et al, 2006). However, given that normal colonic
epithelial cells produce principally VEGFxxxb and the toxicity of
blocking VEGFxxxb in AAC1 adenoma cells, the autocrine role,
may be predominantly due to VEGFxxxb in colonic epithelial cells,
suggesting for the first time a physiologically active role of
VEGFxxxb. Furthermore, the general anti-VEGF antibody bevaci-
zumab was also cytotoxic to AAC1 cells, suggesting that
bevacizumab could potentially have negative effects on normal
colonic epithelium, which expresses high levels of VEGFxxxb.
A life-threatening complication of bevacizumab therapy is
gastrointestinal perforation, the cause of which is unknown
(Hurwitz et al, 2004), but could be due to its effects on survival
of normal colonic epithelial cells, as suggested by the results
shown here.
In summary, we show here that in normal colonic epithelium,
the antiangiogenic isoforms form the majority of VEGF, and VEGF
upregulation in CRC is unique to the proangiogenic isoforms.
These results indicate that the role of VEGF in the normal function
of the colonic mucosa may depend either on the function of
VEGFxxxb, which is still unknown, or the effect of the balance
between the isoforms. We also show that this switch appears to be
an endogenous one to transformation, although environmental
cues such as hypoxia can also induce the switch. Furthermore,
VEGF165b inhibits both colorectal tumour growth (in a VEGF-
dependent manner) and the effect of bevacizumab on that tumour
growth. We further show that bevacizumab binds VEGF165b and
that VEGF165b is an autocrine survival factor for colonic epithelial
cells. These results suggest that anti-VEGF therapy for CRC may be
better targeted to patients with significant excess of proangiogenic
isoforms over antiangiogenic isoforms, and that therapies that
specifically target the proangiogenic isoforms may be more
effective.
ACKNOWLEDGEMENTS
This work was supported by the Royal College of Surgeons of
England (AHRV), Cancer Research UK (AHRV, ER, ABH), The
British Heart Foundation BB2000003 (DOB), North Bristol
Research Foundation, Specific Cancer Research Fund and the
Richard Bright VEGF Research Trust.
REFERENCES
Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D,
Gillatt D, Harper SJ (2002) VEGF165b, an inhibitory splice variant of
vascular endothelial growth factor, is down-regulated in renal cell
carcinoma. Cancer Res 62: 4123–4131
Boehm T, Folkman J, Browder T, O’Reilly M (1997) Antiangiogenic therapy
of experimental cancer does not induce acquired drug resistance. Nature
390: 404–407
Cebe Suarez S, Pieren M, Cariolato L, Arn S, Hoffmann U, Bogucki A,
Manlius C, Wood J, Ballmer-Hofer K (2006) A VEGF-A splice variant
defective for heparan sulfate and neuropilin-1 binding shows attenuated
signaling through VEGFR-2. Cell Mol Life Sci 63: 2067–2077
Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by
acid guanidinium thiocyanate–phenol–chloroform extraction. Anal
Biochem 162: 156–159
Ellis LM, Takahashi Y, Liu W, Shaheen RM (2000) Vascular endothelial
growth factor in human colon cancer: biology and therapeutic
implications. Oncologist 5(Suppl 1): 11–15
Folkman J (1985) Tumor angiogenesis. Adv Cancer Res 43: 175–203
Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other
disease. Nat Med 1: 27–31
Glass CA, Harper SJ, Bates DO (2006) The anti-angiogenic VEGF isoform
VEGF165b transiently increases hydraulic conductivity, probably
through VEGF receptor 1 in vivo. J Physiol 572: 243–257
Griga T, May B, Pfisterer O, Muller KM, Brasch F (2002) Immunohisto-
chemical localization of vascular endothelial growth factor in colonic
mucosa of patients with inflammatory bowel disease. Hepatogastroentero-
logy 49: 116–123
Griga T, Tromm A, Schmiegel W, Pfisterer O, Muller KM, Brasch F (2004)
Collagenous colitis: implications for the role of vascular endothelial
growth factor in repair mechanisms. Eur J Gastroenterol Hepatol 16:
397–402
Griga T, Voigt E, Gretzer B, Brasch F, May B (1999) Increased production
of vascular endothelial growth factor by intestinal mucosa of
patients with inflammatory bowel disease. Hepatogastroenterology 46:
920–923
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim
W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers
B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan,
fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J
Med 350: 2335–2342
Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, Hurwitz
HI, Kabbinavar F, Novotny WF, Hillan KJ, Koeppen H (2005)
Association of k-ras, b-raf, and p53 status with the treatment effect of
bevacizumab. J Natl Cancer Inst 97: 981–989
Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS,
Kabbinavar F, Holden SN, Novotny WF, Frantz GD, Hillan KJ, Koeppen H
(2006) Impact of vascular endothelial growth factor-A expression, throm-
bospondin-2 expression, and microvessel density on the treatment effect of
bevacizumab in metastatic colorectal cancer. JC l i nO n c o l24: 217–227
Kanai T, Konno H, Tanaka T, Baba M, Matsumoto K, Nakamura S, Yukita
A, Asano M, Suzuki H, Baba S (1998) Anti-tumor and anti-metastatic
effects of human-vascular-endothelial-growth-factor-neutralizing anti-
body on human colon and gastric carcinoma xenotransplanted
orthotopically into nude mice. Int J Cancer 77: 933–936
Kendall RL, Thomas KA (1993) Inhibition of vascular endothelial cell
growth factor activity by an endogenously encoded soluble receptor. Proc
Natl Acad Sci USA 90: 10705–10709
Kim KJ, Li B, Houck K, Winer J, Ferrara N (1992) The vascular endothelial
growth factor proteins: identification of biologically relevant regions by
neutralizing monoclonal antibodies. Growth Factors 7: 53–64
Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993)
Inhibition of vascular endothelial growth factor-induced angiogenesis
suppresses tumour growth in vivo. Nature 362: 841–844
Konno H, Tanaka T, Baba M, Kanai T, Matsumoto K, Kamiya K, Nakamura S,
Baba S (1998) Quantitative analysis of vascular endothelial growth factor in
colon cancer. Clinical and experimental. Eur Surg Res 30: 273–278
VEGF165b expression inhibits Avastin treatment
AHR Varey et al
1378
British Journal of Cancer (2008) 98(8), 1366–1379 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sKonopatskaya O, Churchill AJ, Harper SJ, Bates DO, Gardiner TA (2006)
VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits
retinal neovascularization in mice. Mol Vis 12: 626–632
Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C,
Park KR, Ferrara N, Jain RK, Suit HD, Boucher Y (2000) Anti-Vascular
endothelial growth factor treatment augments tumor radiation response
under normoxic or hypoxic conditions. Cancer Res 60: 5565–5570
Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA,
Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP,
Karumanchi SA (2003) Excess placental soluble fms-like tyrosine kinase
1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and
proteinuria in preeclampsia. J Clin Invest 111: 649–658
Miller-Kasprzak E, Jagodzinski PP (2008) 5-Aza-2-deoxycytidine increases
the expression of anti-angiogenic vascular endothelial growth factor 189b
variant in human lung microvascular endothelial cells. Biomed
Pharmacother 62 (in press)
Mulkeen AL, Silva T, Yoo PS, Schmitz JC, Uchio E, Chu E, Cha C (2006)
Short interfering RNA-mediated gene silencing of vascular endothelial
growth factor: effects on cellular proliferation in colon cancer cells.
Arch Surg 141: 367–374; discussion 374
Muller YA, Christinger HW, Keyt BA, de Vos AM (1997) The crystal
structure of vascular endothelial growth factor (VEGF) refined to 1.93 A
resolution: multiple copy flexibility and receptor binding. Structure 5:
1325–1338
Okuda T, Azuma T, Ohtani M, Masaki R, Ito Y, Yamazaki Y, Ito S,
Kuriyama M (2005) Hypoxia-inducible factor 1 alpha and vascular
endothelial growth factor overexpression in ischemic colitis. World
J Gastroenterol 11: 1535–1539
Paraskeva C, Finerty S, Powell S (1988) Immortalization of a human
colorectal adenoma cell line by continuous in vitro passage: possible
involvement of chromosome 1 in tumour progression. Int J Cancer 41:
908–912
Perrin RM, Konopatskaya O, Qiu Y, Harper S, Bates DO, Churchill AJ
(2005) Diabetic retinopathy is associated with a switch in splicing from
anti- to pro-angiogenic isoforms of vascular endothelial growth factor.
Diabetologia 48: 2422–2427
Presta LG, Chen H, O’Connor SJ, Chisholm V, Meng YG, Krummen L,
Winkler M, Ferrara N (1997) Humanization of an anti-vascular
endothelial growth factor monoclonal antibody for the therapy of solid
tumors and other disorders. Cancer Res 57: 4593–4599
Pritchard-Jones RO, Dunn DB, Qiu Y, Varey AH, Orlando A, Rigby H,
Harper SJ, Bates DO (2007) Expression of VEGF(xxx)b, the inhibitory
isoforms of VEGF, in malignant melanoma. Br J Cancer 97: 223–230
Ramaswamy B, Elias AD, Kelbick NT, Dodley A, Morrow M, Hauger M,
Allen J, Rhoades C, Kendra K, Chen HX, Eckhardt SG, Shapiro CL (2006)
Phase II trial of bevacizumab in combination with weekly docetaxel in
metastatic breast cancer patients. Clin Cancer Res 12: 3124–3129
Reinmuth N, Parikh AA, Ahmad SA, Liu W, Stoeltzing O, Fan F, Takeda A,
Akagi M, Ellis LM (2003) Biology of angiogenesis in tumors of the
gastrointestinal tract. Microsc Res Tech 60: 199–207
Wildiers H, Guetens G, De Boeck G, Verbeken E, Landuyt B, Landuyt W, de
Bruijn EA, van Oosterom AT (2003) Effect of antivascular endothelial
growth factor treatment on the intratumoral uptake of CPT-11.
Br J Cancer 88: 1979–1986
Williams AC, Harper SJ, Paraskeva C (1990) Neoplastic transformation of a
human colonic epithelial cell line: in vitro evidence for the adenoma to
carcinoma sequence. Cancer Res 50: 4724–4730
Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO,
Cui TG, Sugiono M, Waine E, Perrin R, Foster R, Digby-Bell J, Shields JD,
Whittles CE, Mushens RE, Gillatt DA, Ziche M, Harper SJ, Bates DO
(2004) VEGF165b, an inhibitory vascular endothelial growth factor splice
variant: mechanism of action, in vivo effect on angiogenesis and
endogenous protein expression. Cancer Res 64: 7822–7835
Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL,
Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of
bevacizumab, an anti-vascular endothelial growth factor antibody, for
metastatic renal cancer. N Engl J Med 349: 427–434
Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK (1996) Time-
dependent vascular regression and permeability changes in established
human tumor xenografts induced by an anti-vascular endothelial growth
factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 93:
14765–14770
VEGF165b expression inhibits Avastin treatment
AHR Varey et al
1379
British Journal of Cancer (2008) 98(8), 1366–1379 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s